NCT05378178 - A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

HS-10381

Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.

Trial Locations (1)

610044

RECRUITING

West China Hospital of Sichuan University, Xi’an